Canada - inglese - Health Canada

odan laboratories ltd - indomethacin - suppository - 100mg - indomethacin 100mg - other nonsteroidal antiimflammatory agents

Australia - inglese - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - captopril -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fosinopril sodium -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; hyprolose; crospovidone; glyceryl behenate - monace is indicated for the treatment of mild to moderate hypertension. monace is effective alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of monace and diuretics used concomitantly are approximately additive. data have not been provided to support the use of monace in severe or renovascular hypertension. heart failure: monace is indicated for the management of heart failure when added to conventional therapy, including diuretics.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; glyceryl behenate - hypertension: treatment of mild to moderate hypertension. fosinopril is effectine alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of fosinopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of fosinopril in severe or renovascular hypertension. heart failure: management of heart failure when added to conventional therapy, including diuretics.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.25mg;  ;  ;  ;  ; digoxin 0.25mg - tablet - 0.25 mg - active: digoxin 0.25mg         excipient: lactose monohydrate magnesium stearate maize starch pregelatinised maize starch purified water rice starch active: digoxin 0.25mg excipient: lactose monohydrate magnesium stearate maize starch purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.05 mg/ml;   - elixir - 0.05 mg/ml - active: digoxin 0.05 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate ethanol lime flavour 70.80.0303 methyl hydroxybenzoate propylene glycol purified water quinoline yellow sucrose - lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.0625mg;  ;  ;  ;  ; digoxin 0.0625mg - tablet - 0.0625 mg - active: digoxin 0.0625mg         excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone pregelatinised maize starch purified water rice starch active: digoxin 0.0625mg excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - irbesartan -